Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis.

Giorgio GandagliaMaxine SunQuoc Dien TrinhAndreas BeckerJonas SchiffmannJim C HuAlberto BrigantiFrancesco MontorsiPaul PerrottePierre I KarakiewiczFiras Abdollah

Published in: BJU international (2014)

RP leads to a significant survival advantage compared with observation in patients with locally advanced disease. The highest benefit was observed in patients with T3b/T4 and Gleason score 8-10 disease.

Keyphrases

prostate cancer
locally advanced
radical prostatectomy
squamous cell carcinoma
rectal cancer
neoadjuvant chemotherapy
free survival
risk assessment
lymph node
climate change
study protocol